Search Result

Results for "

Neuropsychiatric

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5-HT Receptor (2) Adrenergic Receptor (3) Biochemical Assay Reagents (1) Carbonic Anhydrase (1) Casein Kinase (1) Cholinesterase (ChE) (1) COX (1) Dopamine Receptor (4) Dopamine Transporter (1) GABA Receptor (2) GPR52 (1) HDAC (1) Histamine Receptor (4) iGluR (3) Isotope-Labeled Compounds (1) mAChR (3) Monoamine Transporter (1) nAChR (5) Opioid Receptor (2) Phosphodiesterase (PDE) (1) Phospholipase (1) REV-ERB (1) Trace Amine-associated Receptor (TAAR) (2)
By Research Areas:	Cancer (3) Cardiovascular Disease (4) Endocrinology (1) Infection (2) Inflammation/Immunology (6) Metabolic Disease (3) Neurological Disease (38)

By Targets:

5-HT Receptor (2)

Adrenergic Receptor (3)

Biochemical Assay Reagents (1)

Carbonic Anhydrase (1)

Casein Kinase (1)

Cholinesterase (ChE) (1)

COX (1)

Dopamine Receptor (4)

Dopamine Transporter (1)

GABA Receptor (2)

GPR52 (1)

HDAC (1)

Histamine Receptor (4)

iGluR (3)

Isotope-Labeled Compounds (1)

mAChR (3)

Monoamine Transporter (1)

nAChR (5)

Opioid Receptor (2)

Phosphodiesterase (PDE) (1)

Phospholipase (1)

REV-ERB (1)

Trace Amine-associated Receptor (TAAR) (2)

By Research Areas:

Cancer (3)

Cardiovascular Disease (4)

Endocrinology (1)

Infection (2)

Inflammation/Immunology (6)

Metabolic Disease (3)

Neurological Disease (38)

Inhibitors & Agonists

Screening Libraries

Peptides

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-103493

TAK-915	Phosphodiesterase (PDE)	Neurological Disease
TAK-915 is a potent, selective, brain-penetrant and orally active phosphodiesterase 2A (PDE2A) inhibitor with an IC₅₀ of 0.61 nM. TAK-915 is >4100-fold more selectivity for PDE2A than PDE1A. TAK-915 has the potential for neuropsychiatric and neurodegenerative disorders treatment .

HY-117516

SR10067	REV-ERB	Neurological Disease Metabolic Disease
SR10067 is a potent, selective and brain penetrant REV-ERB agonist. SR10067 has high affinity for Rev-Erbβ and Rev-Erbα with IC₅₀ values of 160 nM and 170 nM, respectively. SR10067 can be used for the research of metabolic diseases and neuropsychiatric disorders .

HY-106949

Tazomeline	mAChR	Neurological Disease
Tazomeline is a selective M1 muscarinic receptor agonist. Tazomeline inhibits twitch height in rabbit vas deferens(IC₅₀= 0.001 nM). Tazomeline can be used for research of neuropsychiatric disorders .

HY-116483

MPX-007	iGluR	Neurological Disease
MPX-007 is a GluN2A antagonist (IC₅₀: 27 nM). MPX-007 is a tools to probe GluN2A physiology, and to study neuropsychiatric and developmental disorders .

HY-149481

D4R agonist-1	Dopamine Receptor	Neurological Disease
D4R agonist-1 (Compound 16f) is a D4R partial agonist (K_i: 2.2 nM). D4R agonist-1 is metabolically stable in rat and human liver microsomes. D4R agonist-1 can be used for research of neuropsychiatric disorders .

HY-148224

Pifoxime	COX	Inflammation/Immunology
Pifoxime is a COX-1/2 inhibitor, a non-steroidal anti-inflammatory agent (NSAID). Pifoxime shows anti-inflammatory activity, and can be used in neuropsychiatric research .

HY-155319

μ opioid receptor agonist 3	Opioid Receptor	Neurological Disease
μ opioid receptor agonist 3 (compound 20) is a potent μ opioid receptor (µOR) agonist with an EC₅₀ of 0.87 nM. μ opioid receptor agonist 3 has the potential for pain and neuropsychiatric indications research .

HY-W909149

TAAR1 agonist 3	Trace Amine-associated Receptor (TAAR) Adrenergic Receptor	Neurological Disease
TAAR1 agonist 3 is a trace amine-associated receptor 1 (TAAR1) agonist (pEC₅₀=7.6). TAAR1 agonist 3 is also a full agonist of the α_2A receptor (pEC₅₀=6). TAAR1 agonist 3 can be used in the study of neuropsychiatric diseases .

HY-P5756

CSD-CH2(1,8)-NH2	Opioid Receptor	Neurological Disease
CSD-CH2(1,8)-NH2 is a selective and competitive KOR antagonist (K_i: 6.8 nM). CSD-CH2(1,8)-NH2 inhibits calcium mobilization in DRG neurons. CH2(1,8)-NH2 antagonizes the antinociceptive effect of U50,488. CSD-CH2(1,8)-NH2 can be used for research of neuropsychiatric disorders .

HY-136258

nAChR agonist CMPI hydrochloride	nAChR	Neurological Disease
nAChR agonist CMPI hydrochloride is a potent and selective positive allosteric modulator (PAM) of nAChR containing a α4:α4 subunit interface. nAChR agonist CMPI hydrochloride enhances the response of (α4)₃(β2)₂ nAChR to ACh (10 µM) with an EC₅₀ of 0.26 µM. nAChR agonist CMPI hydrochloride has potential for the research of nicotine dependence and many neuropsychiatric conditions associated with decreased brain cholinergic activity .

HY-B1395

Mecamylamine hydrochloride 3 Publications Verification	nAChR Histamine Receptor	Cardiovascular Disease Neurological Disease
Mecamylamine hydrochloride is an orally active, nonselective, noncompetitive nAChR antagonist. Mecamylamine hydrochloride is also a ganglionic blocker. Mecamylamine hydrochloride can across the blood-brain barrier. Mecamylamine hydrochloride can be used in the research of neuropsychiatric disorders, hypertension, antidepressant area .

HY-B1395A

Mecamylamine	nAChR Histamine Receptor	Cardiovascular Disease Neurological Disease
Mecamylamine is an orally active, nonselective, noncompetitive nAChR antagonist. Mecamylamine is also a ganglionic blocker. Mecamylamine can across the blood-brain barrier. Mecamylamine can be used in the research of neuropsychiatric disorders, hypertension, antidepressant area .

HY-169163

BChE-IN-36	Carbonic Anhydrase Cholinesterase (ChE)	Neurological Disease
hBChE-IN-4 (compound 40) is a potent hCA activator and BChE inhibitor with K_A values of 266, 76.9, 918, 893, 98.0 nM for hCA I, hCA II, hCA IV, hCA VB, hCA VII, IC₅₀ values of 72.1, 4.2 nM for eeAChE, eqBChE, respectively. hBChE-IN-4 shows no cytotoxicity. hBChE-IN-4 shows potent procognitive effects. hBChE-IN-4 has the potential for the research of neurodegenerative diseases and other neuropsychiatric disorders .

HY-W909173

TAAR1 agonist 2	Trace Amine-associated Receptor (TAAR) Histamine Receptor mAChR	Neurological Disease
TAAR1 agonist 2 (compound 30) is a full agonist of trace amine-associated receptor 1 (TAAR1) (pEC₅₀=7.5). TAAR1 agonist 2 also exhibits agonist activity at H1 receptors and activates several members of the muscarinic acetylcholine receptor family, such as the M2 receptor (pEC₅₀=5). TAAR1 agonist 2 can be used in the study of neuropsychiatric diseases .

HY-103213

JP1302 dihydrochloride 1 Publications Verification	Adrenergic Receptor	Neurological Disease Endocrinology
JP1302 dihydrochloride is a potent, selective, high affinity antagonist of the α_2C-adrenoceptor, with a K_b of 16 nM and a K_i of 28 nM for the human α_2C-receptor. JP1302 dihydrochloride shows antidepressant and antipsychotic-like effects. JP1302 dihydrochloride can be used for neuropsychiatric disorders and renal dysfunction research .

HY-103213A

JP1302	Adrenergic Receptor	Neurological Disease
JP1302 is a potent, selective, high affinity antagonist of the α_2C-adrenoceptor, with a K_b of 16 nM and a K_i of 28 nM for the human α_2C-receptor. JP1302 shows antidepressant and antipsychotic-like effects. JP1302 can be used for neuropsychiatric disorders and renal dysfunction research .

HY-B1395R

Mecamylamine hydrochloride (Standard)	nAChR Histamine Receptor	Cardiovascular Disease Neurological Disease
Mecamylamine (hydrochloride) (Standard) is the analytical standard of Mecamylamine (hydrochloride). This product is intended for research and analytical applications. Mecamylamine hydrochloride is an orally active, nonselective, noncompetitive nAChR antagonist. Mecamylamine hydrochloride is also a ganglionic blocker. Mecamylamine hydrochloride can across the blood-brain barrier. Mecamylamine hydrochloride can be used in the research of neuropsychiatric disorders, hypertension, antidepressant area .

HY-148939

MPX-004	iGluR	Neurological Disease
MPX-004 is a potent GluN2A antagonist. MPX-004 inhibits GluN2A-containing NMDA receptors expressed in HEK cells with an IC₅₀ of 79 nM. MPX-004 has no inhibitory effect on GluN2B or GluN2D receptor-mediated responses. MPX-004 has the potential for neuropsychiatric and developmental disorders research .

HY-148104

ACSS2-IN-2 1 Publications Verification	Others	Infection Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
ACSS2-IN-2 is an acyl-CoA synthetase short-chain family member 2 (ACSS2) inhibitor. ACSS2-IN-2 can inhibit ACSS2 activity with an IC₅₀ value of 3.8 nM. ACSS2-IN-2 can be used for the research of several diseases, such as viral infection, metabolic disorders, neuropsychiatric diseases, inflammatory/autoimmune conditions and cancer .

HY-400648

Folic acid methyl ester	Others	Cancer
Folic acid methyl ester is a methyl ester metabolite of folic acid that can be used in the study of neuropsychiatric conditions, such as depression ^{[1] ^.}

HY-154980

GPR52 receptor modulator 1	Others	Neurological Disease
GPR52 receptor modulator 1 (Procedure 1) is a GPR52 receptor modulator with the potential to study neuropsychiatric diseases .

HY-119776

UBP618	iGluR	Neurological Disease
UBP618 is a non-selective N-methyl-D-aspartate inhibitor .

HY-103054

RO5203648	Others	Neurological Disease
RO5203648 is a potent and highly selective partial agonist of TAAR1 (Trace amine-associated receptor 1) with high affinity. RO5203648 demonstrates a novel paradigm for neuropsychiatric research .

HY-14840A

(R)-Phenylpiracetam MRZ 9547	Dopamine Transporter	Neurological Disease Inflammation/Immunology
(R)-Phenylpiracetam (MRZ 9547) is a dopamine transporter (DAT) inhibitor (K_i: 14.8 μM; IC₅₀: 65.5 μM). (R)-Phenylpiracetam can be used for the research of the neurological or neuropsychiatric disorders .

HY-N12125

Entadamide A	Others	Infection
Entadamide A (compound 1) is a tryptophan derivative. Entadamide A prevents tryptophan depletion by inhibiting indoleamine 2, 3-dioxygenase (IDO), thereby inhibiting HIV replication. Entadamide A can be used in drug and neuropsychiatric studies of redesivir [1].

HY-163671

PW0729	GPR52	Neurological Disease
PW0729 (compound 15b) is an orphan GPR52 agonist with potential applications in GPR52 activation, signaling bias, and neuropsychiatric and neurological disorders. The brain exposure characteristics of PW0729 need to be further optimized .

HY-128856

P7C3-OMe	Others	Neurological Disease
P7C3-OMe is a pro-neurogenic compound, has therapeutic benefits in neuropsychiatric and/or neurodegenerative disease. The R-enantiomer of P7C3-OMe is far more active than the S-enantiomer .

HY-103522

AA29504	GABA Receptor	Neurological Disease
AA29504 is a ethyl carbamate with γ-aminobutyric acid (GABA_A(HY-L120) receptor activity. AA29504 inhibits the delivery of the neurotransmitter gamma-aminobutyric acid in the central nervous system. AA29504 can be used to research anxiety, insomnia and other neuropsychiatric diseases .

HY-128584

VU6005806 AZN-00016130	mAChR	Neurological Disease
VU6005806 (AZN-00016130) is a potent muscarnic acethylcholine receptor subtype 4 (M₄) positive allosteric modulator (PAM), with EC₅₀s of 94 nM, 28 nM, 87 nM and 68 nM for human, rat, dog and cyno M₄, respectively. Used in the research of neuropsychiatric disorders .

HY-E70395

Prolyl endopeptidase PE; PEP	Biochemical Assay Reagents	Neurological Disease
Prolyl Endopeptidase, highly active in brain and other tissues, catabolizes proline-containing peptides such as substance P, neurotensin, luteinizing hormone-releasing hormone, thyrotropin releasing hormone, bradykinin and angiotensin II. Prolyl Endopeptidase can be used for study of neuropsychiatric diseases such as stress disorder, depression, and schizophrenia .

HY-B1395S1

Mecamylamine hydrochloride-13C4,15N	Isotope-Labeled Compounds nAChR	Neurological Disease
Mecamylamine (hydrochloride)- ¹³C₄, ¹⁵N is the ¹³C-labeled and ¹⁵N-labeled Mecamylamine hydrochloride. Mecamylamine hydrochloride is an orally active, nonselective, noncompetitive nAChR antagonist that can treat various neuropsychiatric disorders. Mecamylamine hydrochloride is originally used as a ganglionic blocker in treating hypertension. Mecamylamine hydrochloride can easily crosses the blood-brain barrier[1][2].

HY-14856

Atagabalin PD 0200390	GABA Receptor	Neurological Disease
Atagabalin (PD 0200390) is a selective GABA (gamma-aminobutyric acid) receptor agonist with antianxiety and sedative effects. Atagabalin enhances the activity of the GABA receptor by binding to the α2δ subunit of the GABA receptor, thereby increasing the GABA mediated inhibition. This enhancement results in reduced excitability of neurons, helping to reduce anxiety and improve sleep. Atagabalin can be used to study neuropsychiatric disorders, anxiety or sleep disorders .

HY-15977

(S)-P7C3-OMe	Others	Neurological Disease
(S)-P7C3-OMe, P7C3-A20 hydroxylated analog, is the (S)-enantiomer of P7C3-OMe. P7C3-OMe is a pro-neurogenic compound, can be used for the research of neuropsychiatric and/or neurodegenerative disease .

HY-110010

Nafadotride	Dopamine Receptor	Neurological Disease
Nafadotride is a dopamine D3 receptor antagonist. Nafadotrode regulates dopamine signaling primarily by antagonizing dopamine D3 receptors. The dopamine D3 receptor plays an important role in regulating emotion, motivation, reward, and certain motor functions. By blocking these receptors, Nafadotrode may affect neurotransmission processes associated with these functions. Nafadotrode can be used to explore the role of dopamine D3 receptors in various behavioral and neuropsychiatric disorders .

HY-19348

Pimelic Diphenylamide 106 4 Publications Verification RGFA-8; TC-H 106; Histone Deacetylase Inhibitor VII	HDAC Monoamine Transporter	Neurological Disease Cancer
Pimelic Diphenylamide 106 (TC-H 106) is a slow, tight binding class I HDAC inhibitor (inhibits HDAC1, 2, and 3 with IC₅₀ values of 150 nM, 760 nM, and 370 nM, respectively), with no activity against class II HDACs. Pimelic Diphenylamide 106 modulates dopamine concentration and protects dopamine cells by inducing VMAT2 expression. Pimelic Diphenylamide 106 can be used in the study of neuropsychiatric diseases such as attention deficit hyperactivity disorder (ADHD) .

HY-123446

JNJ-42259152	Others	Neurological Disease
JNJ-42259152 is a phosphodiesterase 10A (PDE10A) positron emission tomography (PET) tracer that is specific for PDE10A activity. JNJ-42259152 can be dynamically scanned in healthy volunteers to assess its kinetic properties in the brain. The half-life of JNJ-42259152 in the blood is an average of 90 minutes. JNJ-42259152 has demonstrated reliable binding potential (BPND) in different target areas (such as the lentiform nucleus, caudate nucleus, ventral striatum, etc.), providing an important tool for studying neuropsychiatric diseases .

HY-111241

SV 293	Others	Neurological Disease
SV 293 is a selective antagonist with neutral antagonist activity. SV 293 binds to human D2 receptors with 100-fold higher affinity and has lower affinity for human D3 and D4 dopamine receptor subtypes. SV 293 was found to block the effects of the full agonist quinpirole in forskolin-dependent adenylate acylase inhibition assays and electrophysiological assays. SV 293 can be used as a useful pharmacological tool to study the role of dopamine D2-like receptor subtypes in dopamine pathways associated with neurological, neuropsychiatric and movement disorders .

HY-162336

Casein kinase 1δ-IN-15	Casein Kinase	Neurological Disease
Casein kinase 1δ-IN-15 is an inhibitor for casein kinase 1 (CK1δ), with an IC₅₀ of 0.045 μM .

HY-109112

Brilaroxazine RP5063	Dopamine Receptor 5-HT Receptor	Neurological Disease Inflammation/Immunology
Brilaroxazine (RP5603) is a potent and orally active multimodal dopamine (DA)/serotonin (5-HT) modulator. Brilaroxazine is a partial agonist of dopamine (DA) D2, D3, and D4 receptors, 5-HT1A (K_i=1.5 nM) and 5-HT2A (K_i=2.5 nM), and has antagonist activity at 5-HT2B (K_i=0.19 nM), and 5-HT7 (K_i=2.7 nM) receptors . Brilaroxazine is an atypical antipsychotic agent, and has the potential to improve cognitive impairments in neuropsychiatric and neurological diseases in vivo .

HY-109112R

Brilaroxazine (Standard)	Dopamine Receptor 5-HT Receptor	Neurological Disease Inflammation/Immunology
Brilaroxazine (Standard) is the analytical standard of Brilaroxazine. This product is intended for research and analytical applications. Brilaroxazine (RP5603) is a potent and orally active multimodal dopamine (DA)/serotonin (5-HT) modulator. Brilaroxazine is a partial agonist of dopamine (DA) D2, D3, and D4 receptors, 5-HT1A (K_i=1.5 nM) and 5-HT2A (K_i=2.5 nM), and has antagonist activity at 5-HT2B (K_i=0.19 nM), and 5-HT7 (K_i=2.7 nM) receptors . Brilaroxazine is an atypical antipsychotic agent, and has the potential to improve cognitive impairments in neuropsychiatric and neurological diseases in vivo .

HY-160637

Lp-PLA2-IN-17	Phospholipase	Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology
Lp-PLA2-IN-17 (Compound 39) is an inhibitor of Lp-PLA₂. Lp-PLA2-IN-17 can be used to study disorders involving the hydrolysis of oxidized lipids into two inflammatory substances with the participation of Lp-PLA₂ .

Cat. No.	Product Name

HY-L120

GABA Receptor Compound Library	150 compounds
GABA receptors are a class of receptors that respond to the neurotransmitter gamma-aminobutyric acid (GABA), the chief inhibitory neurotransmitter in the vertebrate central nervous system. There are two classes of GABA receptors: GABAA and GABAB. GABAA receptors are ligand-gated ion channels (also known as ionotropic receptors), whereas GABAB receptors are G protein-coupled receptors (also known asmetabotropic receptors). GABA receptors are significant drug targets in the treatment of neuropsychiatric disorders such as epilepsy, insomnia, and anxiety, as well as in anesthesia in surgical operations. MCE offers a unique collection of 150 GABA receptors inhibitors and activators, which is an efficient tool for neuropsychiatric disorders drugs discovery.

GABA Receptor Compound Library

150 compounds

GABA receptors are a class of receptors that respond to the neurotransmitter gamma-aminobutyric acid (GABA), the chief inhibitory neurotransmitter in the vertebrate central nervous system. There are two classes of GABA receptors: GABAA and GABAB. GABAA receptors are ligand-gated ion channels (also known as ionotropic receptors), whereas GABAB receptors are G protein-coupled receptors (also known asmetabotropic receptors). GABA receptors are significant drug targets in the treatment of neuropsychiatric disorders such as epilepsy, insomnia, and anxiety, as well as in anesthesia in surgical operations.

MCE offers a unique collection of 150 GABA receptors inhibitors and activators, which is an efficient tool for neuropsychiatric disorders drugs discovery.

HY-L121

5-HT Receptor Compound Library	326 compounds
5-HT receptors, also called Serotonin receptors, are a group of G protein-coupled receptors (GPCRs) and ligand-gated ion channels (LGICs) found in the central and peripheral nervous systems. These receptors are now classified into seven families, 5-HT1–7, comprising a total of 14 structurally and pharmacologically distinct mammalian 5-HT receptor subtypes. The 5-HT receptors influence various biological and neurological processes such as aggression, anxiety, appetite, cognition, learning, memory, mood, nausea, sleep, andthermoregulation. The serotonin receptors are the target of a variety of pharmaceutical drugs, including many antidepressants, antipsychotics, anorectics, antiemetics, gastroprokinetic agents, antimigraine agents, hallucinogens, and entactogens. MCE 5-HT Receptor Compound Library consists of 326 5-HT receptor inhibitors and activators, which can be used for neuropsychiatric disorders drugs discovery.

5-HT Receptor Compound Library

326 compounds

5-HT receptors, also called Serotonin receptors, are a group of G protein-coupled receptors (GPCRs) and ligand-gated ion channels (LGICs) found in the central and peripheral nervous systems. These receptors are now classified into seven families, 5-HT1–7, comprising a total of 14 structurally and pharmacologically distinct mammalian 5-HT receptor subtypes. The 5-HT receptors influence various biological and neurological processes such as aggression, anxiety, appetite, cognition, learning, memory, mood, nausea, sleep, andthermoregulation. The serotonin receptors are the target of a variety of pharmaceutical drugs, including many antidepressants, antipsychotics, anorectics, antiemetics, gastroprokinetic agents, antimigraine agents, hallucinogens, and entactogens.

MCE 5-HT Receptor Compound Library consists of 326 5-HT receptor inhibitors and activators, which can be used for neuropsychiatric disorders drugs discovery.

Cat. No.	Product Name	Target	Research Area

HY-P5756

CSD-CH2(1,8)-NH2	Opioid Receptor	Neurological Disease
CSD-CH2(1,8)-NH2 is a selective and competitive KOR antagonist (K_i: 6.8 nM). CSD-CH2(1,8)-NH2 inhibits calcium mobilization in DRG neurons. CH2(1,8)-NH2 antagonizes the antinociceptive effect of U50,488. CSD-CH2(1,8)-NH2 can be used for research of neuropsychiatric disorders .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N12125

Entadamide A	Structural Classification Natural Products Petasites formosanus Kitam. Leguminosae Source classification Plants	Others
Entadamide A (compound 1) is a tryptophan derivative. Entadamide A prevents tryptophan depletion by inhibiting indoleamine 2, 3-dioxygenase (IDO), thereby inhibiting HIV replication. Entadamide A can be used in drug and neuropsychiatric studies of redesivir [1].

Cat. No.	Product Name	Chemical Structure

HY-B1395S1

Mecamylamine hydrochloride-13C4,15N

Mecamylamine (hydrochloride)- ¹³C₄, ¹⁵N is the ¹³C-labeled and ¹⁵N-labeled Mecamylamine hydrochloride. Mecamylamine hydrochloride is an orally active, nonselective, noncompetitive nAChR antagonist that can treat various neuropsychiatric disorders. Mecamylamine hydrochloride is originally used as a ganglionic blocker in treating hypertension. Mecamylamine hydrochloride can easily crosses the blood-brain barrier[1][2].

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks